Association Of Coagulation Factor Ⅶ Gene Polymorphisms And Its Plasma Activity Levels With Venous Thromboembolism

Objective:To investigate the coagulation factor Ⅶ gene R353Q mutation andplasma FⅦa levels in patients with venous thromboembolism.Methods:198patients(including86males and112females, mean age (54.39±15.37) years) diagnosed by VTEwere admitted by the First Affiliated Hospital of Xinjiang Medical University betweenJanuary2008and June2012,and212population(including104males and108females,mean age (53.15±14.53) years) were studied as controls. Polymerase chainreaction-restriction fragment length polymorphism (PCR-RFLP) was applied to detect thepolymorphism of FⅦ gene R353Q and enzyme-linked immuno sorbent assay wasadopted to determine the plasma FⅦa levels, and the association of the polymorphism ofFⅦ with VTE was analyzed.Results:①The frequencies of RR, RQ and QQ were72.73%,26.76%and0.51%in the VTE group while those were74.06%,25.47%and0.47%in thecontrol group. There were no significant differences in the SNP genotyping distributionfrequency between controls and VTE patients (P>0.05).The R-allele frequency (86.11%vs.86.79%) and Q-allele frequency (13.89%vs.13.21%) in the VTE group and controlgroup showed not statistically significant differences, respectively(P>0.05).②Plasma FⅦa levels in VTE group were significantly higher than controls(VTE group：234.39±89.33pg ml，control group：103.60±33.62pg ml，P=0.000). In VTE group, plasma FⅦa levelsin FⅦ gene R/R genotype were statistically higher than R/Q and Q/Q genotype (P <0.05).③Multifactor logistic regression analysis showed that, after adjusting for age, gender,smoking history, dyslipidemia, hypertension, diabetes, and FⅦgenotype, plasma FⅦalevels(OR=0.152，95%CI1.086-1.247， P=0.000), Fibrinogen(OR=2.858，95%CI1.675-4.879，P=0.000) and Smoking (OR=1.623，95%CI1.039-2.009，P=0.001) wereindependent risk factors for VTE patients. Conclusion:The plasma FⅦa levels was higherin VTE patients compared to normal population, and high plasma FⅦa levels may be a common risk factor for VTE. The FⅦ R353Q polymorphism may not be an independentrisk factor for VTE patients.